Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease.
Wobma H, Kapadia M, Kim HT, Alvarez-Calderon F, Baumeister SHC, Duncan C, Forrest S, Gorfinkel L, Huang J, Lehmann LE, Li H, Schwartz M, Koreth J, Ritz J, Kean LS, Whangbo JS.
Blood Adv. 2023 08 22. 7(16):4647-4657. PMID: 37603347